Investment Analysts’ Recent Ratings Changes for Kura Oncology (KURA)

A number of research firms have changed their ratings and price targets for Kura Oncology (NASDAQ: KURA):

  • 10/16/2018 – Kura Oncology was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
  • 10/10/2018 – Kura Oncology was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
  • 10/9/2018 – Kura Oncology was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/29/2018 – Kura Oncology was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/18/2018 – Kura Oncology was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

NASDAQ KURA opened at $15.55 on Friday. The company has a market cap of $603.81 million, a PE ratio of -10.23 and a beta of 4.19. Kura Oncology Inc has a 52 week low of $12.10 and a 52 week high of $24.02. The company has a quick ratio of 10.22, a current ratio of 10.22 and a debt-to-equity ratio of 0.04.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.45) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.45). On average, equities analysts anticipate that Kura Oncology Inc will post -1.73 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in shares of Kura Oncology by 67.0% during the first quarter. Barclays PLC now owns 8,977 shares of the company’s stock valued at $168,000 after acquiring an additional 3,600 shares in the last quarter. Voya Investment Management LLC purchased a new position in shares of Kura Oncology during the second quarter valued at approximately $187,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Kura Oncology during the second quarter valued at approximately $218,000. Element Capital Management LLC purchased a new position in shares of Kura Oncology during the first quarter valued at approximately $238,000. Finally, BB&T Securities LLC purchased a new position in shares of Kura Oncology during the second quarter valued at approximately $291,000. Hedge funds and other institutional investors own 77.28% of the company’s stock.

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Further Reading: What is the yield curve?

Receive News & Ratings for Kura Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply